| . | Pre-HCT . | Month 1 . | Month 2 . | Month 3 . | Month 4 . | Month 8 . | Month 12 . | Month 24 . |
|---|---|---|---|---|---|---|---|---|
| Copies/mL | n = 188 | n = 185 | n = 178 | n = 165 | n = 134 | n = 85 | n = 91 | n = 44 |
| 0 | 183 (97.3%) | 112 (60.5%) | 105 (59.0%) | 110 (66.7%) | 101 (75.4%) | 73 (85.9%) | 82 (90.1%) | 41 (93.2%) |
| 1–9999 | 3 (1.6%) | 67 (36.2%) | 52 (29.2%) | 30 (18.2%) | 20 (14.9%) | 10 (11.8%) | 8 (8.8%) | 3 (6.8%) |
| 10 000–99 999 | 2 (1.1%) | 3 (1.6%) | 16 (9.0%) | 15 (9.1%) | 8 (6.0%) | 2 (2.4%) | 0 (0%) | 0 (0%) |
| ≥100 000 | 0 (0%) | 3 (1.6%) | 5 (2.8%) | 10 (6.1%) | 5 (3.7%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| . | Pre-HCT . | Month 1 . | Month 2 . | Month 3 . | Month 4 . | Month 8 . | Month 12 . | Month 24 . |
|---|---|---|---|---|---|---|---|---|
| Copies/mL | n = 188 | n = 185 | n = 178 | n = 165 | n = 134 | n = 85 | n = 91 | n = 44 |
| 0 | 183 (97.3%) | 112 (60.5%) | 105 (59.0%) | 110 (66.7%) | 101 (75.4%) | 73 (85.9%) | 82 (90.1%) | 41 (93.2%) |
| 1–9999 | 3 (1.6%) | 67 (36.2%) | 52 (29.2%) | 30 (18.2%) | 20 (14.9%) | 10 (11.8%) | 8 (8.8%) | 3 (6.8%) |
| 10 000–99 999 | 2 (1.1%) | 3 (1.6%) | 16 (9.0%) | 15 (9.1%) | 8 (6.0%) | 2 (2.4%) | 0 (0%) | 0 (0%) |
| ≥100 000 | 0 (0%) | 3 (1.6%) | 5 (2.8%) | 10 (6.1%) | 5 (3.7%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
There were 191 participants with at least 1 blood sample tested for viremia: n represents the number of participants tested at each time point.
Abbreviation: HCT, hematopoietic cell transplant.
| . | Pre-HCT . | Month 1 . | Month 2 . | Month 3 . | Month 4 . | Month 8 . | Month 12 . | Month 24 . |
|---|---|---|---|---|---|---|---|---|
| Copies/mL | n = 188 | n = 185 | n = 178 | n = 165 | n = 134 | n = 85 | n = 91 | n = 44 |
| 0 | 183 (97.3%) | 112 (60.5%) | 105 (59.0%) | 110 (66.7%) | 101 (75.4%) | 73 (85.9%) | 82 (90.1%) | 41 (93.2%) |
| 1–9999 | 3 (1.6%) | 67 (36.2%) | 52 (29.2%) | 30 (18.2%) | 20 (14.9%) | 10 (11.8%) | 8 (8.8%) | 3 (6.8%) |
| 10 000–99 999 | 2 (1.1%) | 3 (1.6%) | 16 (9.0%) | 15 (9.1%) | 8 (6.0%) | 2 (2.4%) | 0 (0%) | 0 (0%) |
| ≥100 000 | 0 (0%) | 3 (1.6%) | 5 (2.8%) | 10 (6.1%) | 5 (3.7%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
| . | Pre-HCT . | Month 1 . | Month 2 . | Month 3 . | Month 4 . | Month 8 . | Month 12 . | Month 24 . |
|---|---|---|---|---|---|---|---|---|
| Copies/mL | n = 188 | n = 185 | n = 178 | n = 165 | n = 134 | n = 85 | n = 91 | n = 44 |
| 0 | 183 (97.3%) | 112 (60.5%) | 105 (59.0%) | 110 (66.7%) | 101 (75.4%) | 73 (85.9%) | 82 (90.1%) | 41 (93.2%) |
| 1–9999 | 3 (1.6%) | 67 (36.2%) | 52 (29.2%) | 30 (18.2%) | 20 (14.9%) | 10 (11.8%) | 8 (8.8%) | 3 (6.8%) |
| 10 000–99 999 | 2 (1.1%) | 3 (1.6%) | 16 (9.0%) | 15 (9.1%) | 8 (6.0%) | 2 (2.4%) | 0 (0%) | 0 (0%) |
| ≥100 000 | 0 (0%) | 3 (1.6%) | 5 (2.8%) | 10 (6.1%) | 5 (3.7%) | 0 (0%) | 1 (1.1%) | 0 (0%) |
There were 191 participants with at least 1 blood sample tested for viremia: n represents the number of participants tested at each time point.
Abbreviation: HCT, hematopoietic cell transplant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
